Response Biomedical (V.RBM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Response Biomedical (V.RBM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rainy_Day_Woman who wrote (446)	8/8/2002 12:31:18 PM
From: Dick Martin	Read Replies (1) of 655

From the Press Releease Aug8 '02 a recent study conducted by DRDC Suffield, part of Defence R&D Canada, an agency of the Canadian Department of National Defence, the RAMP(tm) Anthrax Test was demonstrated to have a reliable detection level of less than 4,000 spores. Orders may still be months away Further to our mandate to test and recommend bioterrorism detection systems to first responders, we will conduct further studies to extend and confirm preliminary findings with the RAMP technology." We need official approval or recommendation for RAMP to be taken seriously the Company, in a letter to Dr. John Marburger III, Director, Office of Science and Technology Policy (OSTP), has requested that the White House re-assess its recommendation against the use of all rapid anthrax field tests This does not say anything about the next two cardiac markers which are going into clinical trials so expect separate press releases on these. Affirms that the prostate test is going forward, another big market item. Additional assays under development include tests for the diagnosis and/or monitoring of prostate cancer, therapeutic drugs and environmental agents including botulinum toxin and ricin.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next